AVLNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Avalyn Pharma Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$23.33−0.33 (-1.39%)
Close on Oct 19, 2026
- Market cap
- $691.75M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$23.32 (+233,200%)past year
Weekly closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $691.75M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.74
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Book value per share
- $13.43
- Diluted shares
- 30M
Two years at a glance
Fiscal years 2024 to 2025, USD
Reported period